GlaxoSmithKline Pharmaceuticals (BOM:500660) EV-to-EBIT : 48.97 (As of Jun. 07, 2024)

GlaxoSmithKline Pharmaceuticals EV-to-EBIT Chart

GlaxoSmithKline Pharmaceuticals Annual Data
	Trend	Mar15	Mar16	Mar17	Mar18	Mar19	Mar20	Mar21	Mar22	Mar23	Mar24
EV-to-EBIT		Get a 7-Day Free Trial					64.45	50.87	32.38	24.81	37.99

GlaxoSmithKline Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															24.81	28.09	27.31	43.60	37.99

Competitive Comparison of GlaxoSmithKline Pharmaceuticals's EV-to-EBIT

For the Drug Manufacturers - General subindustry, GlaxoSmithKline Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlaxoSmithKline Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GlaxoSmithKline Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GlaxoSmithKline Pharmaceuticals's EV-to-EBIT falls into.

GlaxoSmithKline Pharmaceuticals EV-to-EBIT Calculation

GlaxoSmithKline Pharmaceuticals's EV-to-EBIT for today is calculated as:

GlaxoSmithKline Pharmaceuticals's current Enterprise Value is ₹400,602 Mil.
GlaxoSmithKline Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,180 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals  (BOM:500660) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

GlaxoSmithKline Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

GlaxoSmithKline Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was ₹310,791 Mil.
GlaxoSmithKline Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹8,180 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlaxoSmithKline Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pharmaceuticals (BOM:500660) Business Description